Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 10/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 6/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350856 | 0.81 | HSP90AB1 (0.46) | MAP2K1MAP2K2CES2CES1GPR27 | |
| SCHEMBL29669985 | 0.81 | CES2 (0.61) | PTPN1CES2CES1 | |
| SCHEMBL962932 | 0.81 | CES2 (0.61) | PTPN1CES2CES1 | |
| SCHEMBL691531 | 0.79 | DGAT1 (0.61) | PTPN1CES2CES1GPR27DGAT1 | |
| SCHEMBL29993519 | 0.79 | DGAT1 (0.61) | PTPN1CES2CES1GPR27DGAT1 | |
| SCHEMBL932166 | 0.79 | PTPN1 (0.48) | PTPN1CES2CES1DGAT1 | |
| SCHEMBL28801246 | 0.78 | MAP2K1 (0.46) | MAP2K1MAP2K2CES2CES1GPR27 | |
| SCHEMBL30217466 | 0.78 | GSK3B (0.50) | PTPN1CES2CES1GSK3B | |
| SCHEMBL3918063 | 0.78 | GSK3B (0.50) | PTPN1CES2CES1GSK3B | |
| SCHEMBL5050035 | 0.78 | GSK3B (0.50) | PTPN1CES2CES1DGAT1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063085-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2234982-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20090170920-A1 | SUBSTITUTED HYDANTOINS | CHEN SHAOQING | 2009-07-02 | — | — | US | disclosed |
| WO-2009080523-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170920-A1 | SUBSTITUTED HYDANTOINS | HNMT, HRH3, BRAF | PTPN1 3614/4885MAP2K1 124/4885MAP2K2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.